{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:14:29Z","timestamp":1788430469695,"version":"build-2803163510"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We present a narrative review of clinical trials investigating the anxiolytic and antidepressant effects of silexan, an active substance derived from lavender oil and summarize nonclinical findings from pharmacological studies supporting its therapeutic use. Six studies investigated the efficacy of the lavender oil in patients with subthreshold and generalized anxiety disorders as well as in mixed anxiety and depressive disorder (MADD). Furthermore, we present data indicating that silexan may influence sleep quality as well as anxiety or depressive disorders in individuals with post-COVID-19. Silexan taken orally at a daily dose of 80\u00a0mg for 10 weeks was significantly superior to placebo in reducing psychic and somatic symptoms of anxiety and was as effective as 0.5\u00a0mg\/d lorazepam and 20\u00a0mg\/d paroxetine. In patients with mild or moderate major depression, silexan was superior to placebo and comparably effective to 50\u00a0mg\/d sertraline. Significant antidepressant effects were also observed in MADD and depression co-morbid with anxiety. The herbal product had a beneficial effect on activities of daily living and health-related quality of life. Adverse events associated with silexan in clinical trials were limited to eructation and mild, transient gastrointestinal complaints. The herbal product was not associated with drug interactions, sedation, sleep disturbance, dependence and abuse potential, sexual dysfunction, weight gain or withdrawal symptoms. Silexan was therefore safe and effective in subthreshold and syndromal anxiety disorders and in major depression.<\/jats:p>","DOI":"10.1007\/s00406-024-01923-8","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T03:03:05Z","timestamp":1729825385000},"page":"1621-1635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data"],"prefix":"10.1007","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-191X","authenticated-orcid":false,"given":"Siegfried","family":"Kasper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"9","key":"1923_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, J\u00f6nsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen H-C (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(9):655\u2013679. https:\/\/doi.org\/10.1016\/j.euroneuro.2011.07.018","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"1923_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators (2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of Disease Study 2019. Lancet Psychiatry 9(2):137\u2013150. https:\/\/doi.org\/10.1016\/s2215-0366(21)00395-3","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"1923_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/acps.12801","volume":"136","author":"E Bui","year":"2017","unstructured":"Bui E, Fava M (2017) From depression to anxiety, and back. Acta Psychiatrica Scandinavica 136(4):341\u2013342. https:\/\/doi.org\/10.1111\/acps.12801","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"1923_CR4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/da.23113","volume":"38","author":"S Saha","year":"2021","unstructured":"Saha S, Lim CCW, Cannon DL, Burton L, Bremner M, Cosgrove P, Huo Y, J. MJ (2021) Co-morbidity between mood and anxiety disorders: a systematic review and meta-analysis. Depress Anxiety 38:286\u2013306. https:\/\/doi.org\/10.1002\/da.23113","journal-title":"Depress Anxiety"},{"issue":"2","key":"1923_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/da.1020","volume":"13","author":"RM Carter","year":"2001","unstructured":"Carter RM, Wittchen HU, Pfister H, Kessler RC (2001) One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 13(2):78\u201388. https:\/\/doi.org\/10.1002\/da.1020","journal-title":"Depress Anxiety"},{"issue":"3","key":"1923_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/yic.0000000000000256","volume":"34","author":"GJ Lyndon","year":"2019","unstructured":"Lyndon GJ, Prieto R, Wajsbrot DB, Allgulander C, Bandelow B (2019) Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Int Clin Psychopharmacol 34(3):110\u2013118. https:\/\/doi.org\/10.1097\/yic.0000000000000256","journal-title":"Int Clin Psychopharmacol"},{"key":"1923_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2016.08.006","volume":"216","author":"K Kircanski","year":"2017","unstructured":"Kircanski K, LeMoult J, Ordaz S, Gotlib IH (2017) Investigating the nature of co-occurring depression and anxiety: comparing diagnostic and dimensional research approaches. J Affect Disord 216:123\u2013135. https:\/\/doi.org\/10.1016\/j.jad.2016.08.006","journal-title":"J Affect Disord"},{"key":"1923_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jad.2013.11.011","volume":"155","author":"AW Braam","year":"2014","unstructured":"Braam AW, Copeland JR, Delespaul PA, Beekman AT, Como A, Dewey M, Fichter M, Holwerda TJ, Lawlor BA, Lobo A, Magnusson H, Prince MJ, Reischies F, Wilson KC, Skoog I (2014) Depression, subthreshold depression and comorbid anxiety symptoms in older europeans: results from the EURODEP concerted action. J Affect Disord 155:266\u2013272. https:\/\/doi.org\/10.1016\/j.jad.2013.11.011","journal-title":"J Affect Disord"},{"key":"1923_CR9","doi-asserted-by":"publisher","first-page":"1348795","DOI":"10.1155\/2022\/1348795","volume":"2022","author":"Y Chen","year":"2022","unstructured":"Chen Y, Tang M, Yuan S, Fu S, Li Y, Li Y, Wang Q, Cao Y, Liu L, Zhang Q (2022) Rhodiola rosea: a therapeutic candidate on cardiovascular diseases. Oxid Med Cell Longev 2022:1348795. https:\/\/doi.org\/10.1155\/2022\/1348795","journal-title":"Oxid Med Cell Longev"},{"issue":"16","key":"1923_CR10","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1017\/s0033291716002300","volume":"46","author":"C Beard","year":"2016","unstructured":"Beard C, Millner AJ, Forgeard MJ, Fried EI, Hsu KJ, Treadway MT, Leonard CV, Kertz SJ, Bj\u00f6rgvinsson T (2016) Network analysis of depression and anxiety symptom relationships in a psychiatric sample. Psychol Med 46(16):3359\u20133369. https:\/\/doi.org\/10.1017\/s0033291716002300","journal-title":"Psychol Med"},{"issue":"12","key":"1923_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/da.22026","volume":"29","author":"TD Zbozinek","year":"2012","unstructured":"Zbozinek TD, Rose RD, Wolitzky-Taylor KB, Sherbourne C, Sullivan G, Stein MB, Roy-Byrne PP, Craske MG (2012) Diagnostic overlap of generalized anxiety disorder and major depressive disorder in a primary care sample. Depress Anxiety 29(12):1065\u20131071. https:\/\/doi.org\/10.1002\/da.22026","journal-title":"Depress Anxiety"},{"key":"1923_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1192\/bjp.186.3.182","volume":"186","author":"M Maj","year":"2005","unstructured":"Maj M (2005) Psychiatric comorbidity: an artefact of current diagnostic systems? Br J Psychiatry 186:182\u2013184. https:\/\/doi.org\/10.1192\/bjp.186.3.182","journal-title":"Br J Psychiatry"},{"key":"1923_CR13","unstructured":"American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5). In: American Psychiatric A, American Psychiatric Association DSMTF (eds) Neurocognitive disorders. vol Accessed from https:\/\/nla.gov.au\/nla.cat-vn6261708, 5th edn. American Psychiatric Association, Arlington, V.A"},{"key":"1923_CR14","unstructured":"World Health Organization (2019) ICD-11: International classification of diseases (11th revision)"},{"issue":"7","key":"1923_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1080\/02699931.2017.1330255","volume":"32","author":"MW Eysenck","year":"2018","unstructured":"Eysenck MW, Fajkowska M (2018) Anxiety and depression: toward overlapping and distinctive features. Cogn Emot 32(7):1391\u20131400. https:\/\/doi.org\/10.1080\/02699931.2017.1330255","journal-title":"Cogn Emot"},{"issue":"11","key":"1923_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1037\/bul0000111","volume":"143","author":"NC Jacobson","year":"2017","unstructured":"Jacobson NC, Newman MG (2017) Anxiety and depression as bidirectional risk factors for one another: a meta-analysis of longitudinal studies. Psychol Bull 143(11):1155\u20131200. https:\/\/doi.org\/10.1037\/bul0000111","journal-title":"Psychol Bull"},{"issue":"6","key":"1923_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4088\/pcc.v03n0609","volume":"3","author":"RM Hirschfeld","year":"2001","unstructured":"Hirschfeld RM (2001) The comorbidity of major depression and anxiety disorders: Recognition and Management in Primary Care. Prim Care Companion J Clin Psychiatry 3(6):244\u2013254. https:\/\/doi.org\/10.4088\/pcc.v03n0609","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"1923_CR18","doi-asserted-by":"publisher","unstructured":"Buntrock C, Ebert DD, Lehr D, Smit F, Riper H, Berking M, Cuijpers P (2016) Effect of a web-based guided self-help intervention for Prevention of Major Depression in adults with Subthreshold Depression. JAMA 315(17). https:\/\/doi.org\/10.1001\/jama.2016.4326","DOI":"10.1001\/jama.2016.4326"},{"key":"1923_CR19","doi-asserted-by":"publisher","unstructured":"Volz H-P, Saliger J, Kasper S, M\u00f6ller H-J, Seifritz E (2021) Subsyndromal generalised anxiety disorder: operationalisation and epidemiology - a systematic literature survey. Int J Psychiatry Clin Pract 1\u201310. https:\/\/doi.org\/10.1080\/13651501.2021.1941120","DOI":"10.1080\/13651501.2021.1941120"},{"issue":"4","key":"1923_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/15622970209150621","volume":"3","author":"B Bandelow","year":"2002","unstructured":"Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety O-C, Posttraumatic Stress D (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3(4):171\u2013199. https:\/\/doi.org\/10.3109\/15622970209150621","journal-title":"World J Biol Psychiatry"},{"key":"1923_CR21","doi-asserted-by":"publisher","first-page":"212290","DOI":"10.7573\/dic.212290","volume":"4","author":"D Santarsieri","year":"2015","unstructured":"Santarsieri D, Schwartz TL (2015) Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context 4:212290. https:\/\/doi.org\/10.7573\/dic.212290","journal-title":"Drugs Context"},{"issue":"7","key":"1923_CR22","first-page":"2121","volume":"61","author":"LP Longo","year":"2000","unstructured":"Longo LP, Johnson B (2000) Addiction: part I. benzodiazepines\u2013side effects, abuse risk and alternatives. Am Family Phys 61(7):2121\u20132128","journal-title":"Am Family Phys"},{"issue":"1","key":"1923_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1461145705006358","volume":"10","author":"DS Baldwin","year":"2007","unstructured":"Baldwin DS, Montgomery SA, Nil R, Lader M (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10(1):73\u201384. https:\/\/doi.org\/10.1017\/S1461145705006358","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1923_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF02850015","volume":"19","author":"L Tamam","year":"2002","unstructured":"Tamam L, Ozpoyraz N (2002) Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther 19(1):17\u201326. https:\/\/doi.org\/10.1007\/BF02850015","journal-title":"Adv Ther"},{"issue":"1","key":"1923_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neuron.2014.03.016","volume":"82","author":"BA Simms","year":"2014","unstructured":"Simms BA, Zamponi GW (2014) Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron 82(1):24\u201345. https:\/\/doi.org\/10.1016\/j.neuron.2014.03.016","journal-title":"Neuron"},{"issue":"4","key":"1923_CR26","doi-asserted-by":"publisher","first-page":"e59998","DOI":"10.1371\/journal.pone.0059998","volume":"8","author":"AM Schuwald","year":"2013","unstructured":"Schuwald AM, N\u00f6ldner M, Wilmes T, Klugbauer N, Leuner K, M\u00fcller WE (2013) Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS ONE 8(4):e59998. https:\/\/doi.org\/10.1371\/journal.pone.0059998","journal-title":"PLoS ONE"},{"key":"1923_CR27","first-page":"3","volume":"22","author":"WE Mueller","year":"2015","unstructured":"Mueller WE, Schuwald A, Noeldner M, Kasper S, Friedland K (2015) Pharmakologische Grundlagen Der Therapeutischen Anwendung Von Silexan (Lasea\u00ae). [Pharmacological basis of the therapeutic use of Silexan (Lasea\u00ae)]. Psychopharmakotherapie 22:3\u201314","journal-title":"Psychopharmakotherapie"},{"issue":"3","key":"1923_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ijnp\/pyaa064","volume":"24","author":"E Seifritz","year":"2021","unstructured":"Seifritz E, M\u00f6ller H-J, Volz H-P, M\u00fcller WE, Hopyan T, Wacker A, Schl\u00e4fke S, Kasper S (2021) No abuse potential of Silexan in healthy recreational drug users: a randomized controlled trial. Int J Neuropsychopharmacol 24(3):171\u2013180. https:\/\/doi.org\/10.1093\/ijnp\/pyaa064","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1923_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","volume":"30","author":"O Schjerning","year":"2016","unstructured":"Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J (2016) Abuse potential of Pregabalin: a systematic review. CNS Drugs 30(1):9\u201325. https:\/\/doi.org\/10.1007\/s40263-015-0303-6","journal-title":"CNS Drugs"},{"issue":"12","key":"1923_CR30","doi-asserted-by":"publisher","first-page":"P654","DOI":"10.1055\/s-0030-1264952","volume":"76","author":"J Kehr","year":"2010","unstructured":"Kehr J, Yoshitake T, Koch E, Noeldner M (2010) Effects of intraperitoneal administration of Silexan, an essential oil from flowers of Lavandula angustifolia on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex of freely moving rats. Planta Med 76(12):P654. https:\/\/doi.org\/10.1055\/s-0030-1264952","journal-title":"Planta Med"},{"issue":"4","key":"1923_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu063","volume":"18","author":"P Baldinger","year":"2015","unstructured":"Baldinger P, H\u00f6flich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Lanzenberger R, Kasper S (2015) Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol 18(4):1\u20139. https:\/\/doi.org\/10.1093\/ijnp\/pyu063","journal-title":"Int J Neuropsychopharmacol"},{"issue":"11","key":"1923_CR32","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/mp.2008.35","volume":"14","author":"C Spindelegger","year":"2009","unstructured":"Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M, Moser U, Holik A, Pezawas L, Kletter K, Kasper S (2009) Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry 14(11):1040\u20131050. https:\/\/doi.org\/10.1038\/mp.2008.35","journal-title":"Mol Psychiatry"},{"key":"1923_CR33","doi-asserted-by":"publisher","unstructured":"Fonseca ECM, Ferreira LR, Figueiredo PLB, Maia C, Setzer WN, Da Silva JKR (2023) Antidepressant effects of essential oils: a review of the past Decade (2012\u20132022) and Molecular Docking Study of their Major Chemical Components. Int J Mol Sci 24(11). https:\/\/doi.org\/10.3390\/ijms24119244","DOI":"10.3390\/ijms24119244"},{"key":"1923_CR34","doi-asserted-by":"publisher","unstructured":"Somrudee S, Dawrung S, Chantana M (2017) Subchronic Administration of Linalool decreases depressive-like Behaviour in restrained rats. J Pharm Pharmacol 5(7). https:\/\/doi.org\/10.17265\/2328-2150\/2017.07.002","DOI":"10.17265\/2328-2150\/2017.07.002"},{"issue":"7","key":"1923_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1001\/archpsyc.1997.01830190015002","volume":"54","author":"RS Duman","year":"1997","unstructured":"Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54(7):597\u2013606. https:\/\/doi.org\/10.1001\/archpsyc.1997.01830190015002","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1923_CR36","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41380-019-0615-x","volume":"25","author":"RB Price","year":"2020","unstructured":"Price RB, Duman R (2020) Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Mol Psychiatry 25(3):530\u2013543. https:\/\/doi.org\/10.1038\/s41380-019-0615-x","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1923_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/a-1293-8585","volume":"54","author":"K Friedland","year":"2021","unstructured":"Friedland K, Silani G, Schuwald A, Stockburger C, Koch E, N\u00f6ldner M, M\u00fcller WE (2021) Neurotrophic properties of Silexan, an essential oil from the flowers of lavender-preclinical evidence for antidepressant-like properties. Pharmacopsychiatry 54(1):37\u201346. https:\/\/doi.org\/10.1055\/a-1293-8585","journal-title":"Pharmacopsychiatry"},{"key":"1923_CR38","doi-asserted-by":"publisher","first-page":"104899","DOI":"10.1016\/j.neuint.2020.104899","volume":"143","author":"WE M\u00fcller","year":"2021","unstructured":"M\u00fcller WE, Sillani G, Schuwald A, Friedland K (2021) Pharmacological basis of the anxiolytic and antidepressant properties of Silexan\u00ae, an essential oil from the flowers of lavender. Neurochem Int 143:104899. https:\/\/doi.org\/10.1016\/j.neuint.2020.104899","journal-title":"Neurochem Int"},{"issue":"1","key":"1923_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/ndt.s2380","volume":"4","author":"Y Dwivedi","year":"2008","unstructured":"Dwivedi Y, Pandey GN (2008) Adenylyl cyclase-cyclicAMP signaling in mood disorders: role of the crucial phosphorylating enzyme protein kinase A. Neuropsychiatr Dis Treat 4(1):161\u2013176. https:\/\/doi.org\/10.2147\/ndt.s2380","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1923_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neulet.2019.02.042","volume":"701","author":"DI Sanchez-Vidana","year":"2019","unstructured":"Sanchez-Vidana DI, Po KK, Fung TK, Chow JK, Lau WK, So PK, Lau BW, Tsang HW (2019) Lavender essential oil ameliorates depression-like behavior and increases neurogenesis and dendritic complexity in rats. Neurosci Lett 701:180\u2013192. https:\/\/doi.org\/10.1016\/j.neulet.2019.02.042","journal-title":"Neurosci Lett"},{"issue":"6","key":"1923_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/YIC.0b013e32833b3242","volume":"25","author":"S Kasper","year":"2010","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz HP, M\u00f6ller HJ, Dienel A, Schl\u00e4fke S (2010) Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of \u2018subsyndromal\u2019 anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 25(6):277\u2013287. https:\/\/doi.org\/10.1097\/YIC.0b013e32833b3242","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"1923_CR42","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.euroneuro.2015.07.024","volume":"25","author":"S Kasper","year":"2015","unstructured":"Kasper S, Anghelescu I, Dienel A (2015) Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep - A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 25(11):1960\u20131967. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.07.024","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"1923_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.euroneuro.2015.12.002","volume":"26","author":"S Kasper","year":"2016","unstructured":"Kasper S, Volz HP, Dienel A, Schlafke S (2016) Efficacy of Silexan in mixed anxiety-depression - A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 26(2):331\u2013340. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.12.002","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"1923_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.phymed.2009.10.006","volume":"17","author":"H Woelk","year":"2010","unstructured":"Woelk H, Schl\u00e4fke S (2010) A multi-center, double-blind, randomised study of the lavender oil preparation silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 17(2):94\u201399. https:\/\/doi.org\/10.1016\/j.phymed.2009.10.006","journal-title":"Phytomedicine"},{"issue":"06","key":"1923_CR45","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1017\/s1461145714000017","volume":"17","author":"S Kasper","year":"2014","unstructured":"Kasper S, Gastpar M, M\u00fcller WE, Volz H-P, M\u00f6ller H-J, Schl\u00e4fke S, Dienel A (2014) Lavender oil preparation silexan is effective in generalized anxiety disorder \u2013 a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 17(06):859\u2013869. https:\/\/doi.org\/10.1017\/s1461145714000017","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"1923_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/YIC.0000000000000176","volume":"32","author":"S Kasper","year":"2017","unstructured":"Kasper S, M\u00f6ller HJ, Volz HP, Schl\u00e4fke S, Dienel A (2017) Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. Int Clin Psychopharmacol 32(4):195\u2013204. https:\/\/doi.org\/10.1097\/YIC.0000000000000176","journal-title":"Int Clin Psychopharmacol"},{"key":"1923_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50\u201355","journal-title":"Br J Med Psychol"},{"key":"1923_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-022-01547-w","author":"M Dold","year":"2023","unstructured":"Dold M, Bartova L, Volz HP, Seifritz E, M\u00f6ller HJ, Schl\u00e4fke S, Kasper S (2023) Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-022-01547-w","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"1923_CR49","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0033-3182(71)71479-0","volume":"12","author":"WW Zung","year":"1971","unstructured":"Zung WW (1971) A rating instrument for anxiety disorders. Psychosomatics 12(6):371\u2013379","journal-title":"Psychosomatics"},{"key":"1923_CR50","first-page":"100","volume":"17","author":"L Covi","year":"1981","unstructured":"Covi L, Rickels K, Lipman RS, McNair DM, Smith VK, Downing R, Kahn R, Fisher S (1981) Effects of psychotropic agents on primary depression. Psychopharmacol Bull 17:100\u2013103","journal-title":"Psychopharmacol Bull"},{"issue":"6","key":"1923_CR51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67(6):361\u2013370","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"1923_CR52","first-page":"217","volume-title":"EDCEU Assessment in Psychopharmacology","author":"National Institute of Mental Health","year":"1970","unstructured":"National Institute of Mental Health (1970) 12 - CGI. Clinical global impressions. In: Guy W (ed) EDCEU Assessment in Psychopharmacology. U.S. National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, Md., pp 217\u2013222"},{"issue":"4","key":"1923_CR53","doi-asserted-by":"publisher","first-page":"e01997","DOI":"10.1002\/brb3.1997","volume":"11","author":"R von K\u00e4nel","year":"2021","unstructured":"von K\u00e4nel R, Kasper S, Bondolfi G, Holsboer-Trachsler E, H\u00e4ttenschwiler J, Hatzinger M, Imboden C, Heitlinger E, Seifritz E (2021) Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: a meta-analysis. Brain Behav 11(4):e01997. https:\/\/doi.org\/10.1002\/brb3.1997","journal-title":"Brain Behav"},{"issue":"6","key":"1923_CR54","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 30(6):473\u2013483","journal-title":"Med Care"},{"key":"1923_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-024-01783-2","author":"S Kasper","year":"2024","unstructured":"Kasper S, Volz HP, Moller HJ, Schlafke S, Klement S, Anghelescu IG, Seifritz E (2024) Lavender oil preparation silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-024-01783-2","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1923_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389","journal-title":"Br J Psychiatry"},{"key":"1923_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","volume":"3","author":"DV Sheehan","year":"1996","unstructured":"Sheehan DV, Harnett-Sheehan K, Raj BA (1996) The measurement of disability. Int Clin Psychopharmacol 11 Suppl 3:89\u201395. https:\/\/doi.org\/10.1097\/00004850-199606003-00015","journal-title":"Int Clin Psychopharmacol 11 Suppl"},{"issue":"4","key":"1923_CR58","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","volume":"6","author":"M Hamilton","year":"1967","unstructured":"Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6(4):278\u2013296","journal-title":"Br J Soc Clin Psychol"},{"issue":"1","key":"1923_CR59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00406-022-01390-z","volume":"273","author":"L Bartova","year":"2023","unstructured":"Bartova L, Dold M, Volz HP, Seifritz E, Moller HJ, Kasper S (2023) Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. Eur Arch Psychiatry Clin Neurosci 273(1):51\u201363. https:\/\/doi.org\/10.1007\/s00406-022-01390-z","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"1923_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/s0887-6185(03)00031-8","volume":"18","author":"L B\u00e9langer","year":"2004","unstructured":"B\u00e9langer L, Morin CM, Langlois F, Ladouceur R (2004) Insomnia and generalized anxiety disorder: effects of cognitive behavior therapy for gad on insomnia symptoms. J Anxiety Disord 18(4):561\u2013571. https:\/\/doi.org\/10.1016\/s0887-6185(03)00031-8","journal-title":"J Anxiety Disord"},{"key":"1923_CR61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ajp.2014.09.003","volume":"12","author":"R Gupta","year":"2014","unstructured":"Gupta R, Zalai D, Spence DW, BaHammam AS, Ramasubramanian C, Monti JM, Pandi-Perumal SR (2014) When insomnia is not just insomnia: the deeper correlates of disturbed sleep with reference to DSM-5. Asian J Psychiatr 12:23\u201330. https:\/\/doi.org\/10.1016\/j.ajp.2014.09.003","journal-title":"Asian J Psychiatr"},{"issue":"4","key":"1923_CR62","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1017\/s1461145712000922","volume":"16","author":"E Holsboer-Trachsler","year":"2013","unstructured":"Holsboer-Trachsler E, Prieto R (2013) Effects of Pregabalin on sleep in generalized anxiety disorder. Int J Neuropsychopharmacol 16(4):925\u2013936. https:\/\/doi.org\/10.1017\/s1461145712000922","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"1923_CR63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/15622975.2021.2013092","volume":"23","author":"E Seifritz","year":"2022","unstructured":"Seifritz E, Kasper S, M\u00f6ller HJ, Volz HP, M\u00fcller WE, Eckert A, Hatzinger M (2022) Effect of anxiolytic drug silexan on sleep - a narrative review. World J Biol Psychiatry 23(7):493\u2013500. https:\/\/doi.org\/10.1080\/15622975.2021.2013092","journal-title":"World J Biol Psychiatry"},{"key":"1923_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jpsychires.2019.04.013","volume":"115","author":"E Seifritz","year":"2019","unstructured":"Seifritz E, Schl\u00e4fke S, Holsboer-Trachsler E (2019) Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect. J Psychiatr Res 115::69\u201374. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.04.013","journal-title":"J Psychiatr Res"},{"key":"1923_CR65","doi-asserted-by":"publisher","unstructured":"Kr\u00fcger T, Becker EM, Kostev K (2022) Prescription of Silexan is Associated with less frequent general practitioner repeat consultations due to disturbed sleep compared to benzodiazepine receptor agonists: a retrospective database analysis. Healthc (Basel) 11(1). https:\/\/doi.org\/10.3390\/healthcare11010077","DOI":"10.3390\/healthcare11010077"},{"key":"1923_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.euroneuro.2022.03.003","volume":"58","author":"AF Paez","year":"2022","unstructured":"Paez AF, Nicolalde B, Esquetini-Vernon C, Lara-Taranchenko Y, Zambrano K, Ocampo J, Fusaro S, Capa G, Caicedo A (2022) Psychiatric disorders in Post-acute COVID-syndrome (PDPACS): recommendations for health care professionals. Eur Neuropsychopharmacol 58:100\u2013102. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.03.003","journal-title":"Eur Neuropsychopharmacol"},{"key":"1923_CR67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.euroneuro.2023.02.015","volume":"70","author":"L Bartova","year":"2023","unstructured":"Bartova L, Dold M, Fugger G, Weidenauer A, Rujescu D, Kasper S (2023) Silexan for treatment of anxiety and depression in the context of COVID-19. Eur Neuropsychopharmacol 70:47\u201348. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.02.015","journal-title":"Eur Neuropsychopharmacol"},{"key":"1923_CR68","doi-asserted-by":"publisher","unstructured":"Kasper S, Eckert A, Moller HJ, Volz HP, Seifritz E (2023) Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan. Int J Psychiatry Clin Pract 1\u20137. https:\/\/doi.org\/10.1080\/13651501.2023.2187308","DOI":"10.1080\/13651501.2023.2187308"},{"issue":"1","key":"1923_CR69","doi-asserted-by":"publisher","first-page":"18042","DOI":"10.1038\/s41598-019-54529-9","volume":"9","author":"WS Yap","year":"2019","unstructured":"Yap WS, Dolzhenko AV, Jalal Z, Hadi MA, Khan TM (2019) Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: a network meta-analysis. Sci Rep 9(1):18042. https:\/\/doi.org\/10.1038\/s41598-019-54529-9","journal-title":"Sci Rep"},{"key":"1923_CR70","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jpsychires.2020.10.028","volume":"136","author":"HJ M\u00f6ller","year":"2021","unstructured":"M\u00f6ller HJ, Volz HP, Seifritz E, M\u00fcller H, Kenntner-Mabiala R, Kaussner Y, Schoch S, Kasper S (2021) Silexan does not affect driving performance after single and multiple dose applications: results from a double-blind, placebo and reference-controlled study in healthy volunteers. J Psychiatr Res 136:543\u2013551. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.10.028","journal-title":"J Psychiatr Res"},{"issue":"3","key":"1923_CR71","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/13651501.2017.1301488","volume":"21","author":"M Gastpar","year":"2017","unstructured":"Gastpar M, M\u00fcller WE, Volz HP, M\u00f6ller HJ, Schl\u00e4fke S, Dienel A, Kasper S (2017) Silexan does not cause withdrawal symptoms even when abruptly discontinued. Int J Psychiatry Clin Pract 21(3):177\u2013180. https:\/\/doi.org\/10.1080\/13651501.2017.1301488","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"5","key":"1923_CR72","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1124\/dmd.112.050203","volume":"41","author":"O Doroshyenko","year":"2013","unstructured":"Doroshyenko O, Rokitta D, Zadoyan G, Klement S, Schl\u00e4fke S, Dienel A, Gramatt\u00e9 T, L\u00fcck H, Fuhr U (2013) Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P-450 enzymes in healthy volunteers. Drug Metab Dispos 41(5):987\u2013993. https:\/\/doi.org\/10.1124\/dmd.112.050203","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1923_CR73","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40268-014-0065-5","volume":"14","author":"D Heger-Mahn","year":"2014","unstructured":"Heger-Mahn D, Pabst G, Dienel A, Schlafke S, Klipping C (2014) No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol\/levonorgestrel combination. Drugs R D 14(4):265\u2013272. https:\/\/doi.org\/10.1007\/s40268-014-0065-5","journal-title":"Drugs R D"},{"issue":"1","key":"1923_CR74","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12991-023-00486-7","volume":"22","author":"S Li","year":"2023","unstructured":"Li S, Zhang X, Cai Y, Zheng L, Pang H, Lou L (2023) Sex difference in incidence of major depressive disorder: an analysis from the global burden of Disease Study 2019. Ann Gen Psychiatry 22(1):53. https:\/\/doi.org\/10.1186\/s12991-023-00486-7","journal-title":"Ann Gen Psychiatry"},{"key":"1923_CR75","unstructured":"De Mey C, Dienel A (2013) Silexan ist sicher bei eingeschr\u00e4nkter Nierenfunktion. [Silexan is safe in patients with impaired renal function.] English translation of Original publication provided by Dr. Willmar Schwabe. NeuroGeriatrie 10"},{"issue":"6","key":"1923_CR76","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/15622975.2021.2013041","volume":"23","author":"J Sarris","year":"2022","unstructured":"Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, Akhondzadeh S, Benedetti F, Caneo C, Cramer H, Cribb L, de Manincor M, Dean O, Deslandes AC, Freeman MP, Gangadhar B, Harvey BH, Kasper S, Lake J, Lopresti A, Lu L, Metri NJ, Mischoulon D, Ng CH, Nishi D, Rahimi R, Seedat S, Sinclair J, Su KP, Zhang ZJ, Berk M (2022) Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: the World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and anxiety treatments (CANMAT) taskforce. World J Biol Psychiatry 23(6):424\u2013455. https:\/\/doi.org\/10.1080\/15622975.2021.2013041","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"1923_CR77","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00406-017-0852-4","volume":"269","author":"HJ M\u00f6ller","year":"2019","unstructured":"M\u00f6ller HJ, Volz HP, Dienel A, Schl\u00e4fke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 269(2):183\u2013193. https:\/\/doi.org\/10.1007\/s00406-017-0852-4","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"1923_CR78","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/15622975.2017.1331046","volume":"19","author":"S Kasper","year":"2018","unstructured":"Kasper S, M\u00fcller WE, Volz HP, M\u00f6ller HJ, Koch E, Dienel A (2018) Silexan in anxiety disorders: clinical data and pharmacological background. World J Biol Psychiatry 19(6):412\u2013420. https:\/\/doi.org\/10.1080\/15622975.2017.1331046","journal-title":"World J Biol Psychiatry"},{"key":"1923_CR79","doi-asserted-by":"publisher","first-page":"104899","DOI":"10.1016\/j.neuint.2020.104899","volume":"143","author":"WE M\u00fcller","year":"2021","unstructured":"M\u00fcller WE, Sillani G, Schuwald A, Friedland K (2021) Pharmacological basis of the anxiolytic and antidepressant properties of Silexan(R), an essential oil from the flowers of lavender. Neurochem Int 143:104899. https:\/\/doi.org\/10.1016\/j.neuint.2020.104899","journal-title":"Neurochem Int"},{"issue":"1","key":"1923_CR80","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/13651501.2022.2087530","volume":"27","author":"HP Volz","year":"2023","unstructured":"Volz HP, Stirnweiss J, Kasper S, Moller HJ, Seifritz E (2023) Subthreshold depression - concept, operationalisation and epidemiological data. A scoping review. Int J Psychiatry Clin Pract 27(1):92\u2013106. https:\/\/doi.org\/10.1080\/13651501.2022.2087530","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1923_CR81","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-244X-14-128","volume":"14","author":"H Haller","year":"2014","unstructured":"Haller H, Cramer H, Lauche R, Gass F, Dobos GJ (2014) The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. BMC Psychiatry 14:128. https:\/\/doi.org\/10.1186\/1471-244X-14-128","journal-title":"BMC Psychiatry"},{"key":"1923_CR82","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1471-244x-12-181","volume":"12","author":"MR Rodr\u00edguez","year":"2012","unstructured":"Rodr\u00edguez MR, Nuevo R, Chatterji S, Ayuso-Mateos JL (2012) Definitions and factors associated with subthreshold depressive conditions: a systematic review. BMC Psychiatry 12:181. https:\/\/doi.org\/10.1186\/1471-244x-12-181","journal-title":"BMC Psychiatry"},{"issue":"S1","key":"1923_CR83","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.5694\/j.1326-5377.2002.tb04287.x","volume":"175","author":"G Andrews","year":"2001","unstructured":"Andrews G, Carter GL (2001) What people say about their general practitioners\u2019 treatment of anxiety and depression. Med J Aust 175(S1):S48\u201351. https:\/\/doi.org\/10.5694\/j.1326-5377.2002.tb04287.x","journal-title":"Med J Aust"},{"issue":"6","key":"1923_CR84","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):593\u2013602. https:\/\/doi.org\/10.1001\/archpsyc.62.6.593","journal-title":"Arch Gen Psychiatry"},{"key":"1923_CR85","doi-asserted-by":"publisher","unstructured":"Bekker MH, van Mens-Verhulst J (2007) Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend Med 4 Suppl B:S 178\u2013193. https:\/\/doi.org\/10.1016\/s1550-8579(07)80057-x","DOI":"10.1016\/s1550-8579(07)80057-x"},{"issue":"4","key":"1923_CR86","doi-asserted-by":"publisher","first-page":"368504221135469","DOI":"10.1177\/00368504221135469","volume":"105","author":"NZ Farhane-Medina","year":"2022","unstructured":"Farhane-Medina NZ, Luque B, Tabernero C, Castillo-Mayen R (2022) Factors associated with gender and sex differences in anxiety prevalence and comorbidity: a systematic review. Sci Prog 105(4):368504221135469. https:\/\/doi.org\/10.1177\/00368504221135469","journal-title":"Sci Prog"},{"issue":"1","key":"1923_CR87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12888-023-04583-5","volume":"23","author":"L Lu","year":"2023","unstructured":"Lu L, Shen H, Tan L, Huang Q, Chen Q, Liang M, He L, Zhou Y (2023) Prevalence and factors associated with anxiety and depression among community-dwelling older adults in Hunan, China: a cross-sectional study. BMC Psychiatry 23(1):107. https:\/\/doi.org\/10.1186\/s12888-023-04583-5","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1923_CR88","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/pcc.v03n0105","volume":"3","author":"JM Ferguson","year":"2001","unstructured":"Ferguson JM (2001) SSRI antidepressant medications: adverse effects and Tolerability. Prim Care Companion J Clin Psychiatry 3(1):22\u201327. https:\/\/doi.org\/10.4088\/pcc.v03n0105","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"11\u201312","key":"1923_CR89","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10354-015-0360-y","volume":"165","author":"S Kasper","year":"2015","unstructured":"Kasper S (2015) Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. Wien Med Wochenschr 165(11\u201312):217\u2013228. https:\/\/doi.org\/10.1007\/s10354-015-0360-y","journal-title":"Wien Med Wochenschr"},{"issue":"3\u20134","key":"1923_CR90","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10354-012-0164-2","volume":"163","author":"V Kumar","year":"2013","unstructured":"Kumar V (2013) Characterization of anxiolytic and neuropharmacological activities of Silexan. Wien Med Wochenschr 163(3\u20134):89\u201394. https:\/\/doi.org\/10.1007\/s10354-012-0164-2","journal-title":"Wien Med Wochenschr"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01923-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-024-01923-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01923-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:15:56Z","timestamp":1759752956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-024-01923-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1923"],"URL":"https:\/\/doi.org\/10.1007\/s00406-024-01923-8","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable since it is a review of published data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"In the past 3 years Siegfried Kasper served as a consultant or on advisory boards for Angelini, Biogen, Boehringer, Esai, Janssen, IQVIA, Mylan, Recordati, Rovi, Sage and Schwabe; and he has served on speakers bureaus for Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Recordati, Schwabe, Servier, Sothema, and Sun Pharma. Anne Eckert received grant support from Schwabe and OM Pharma, served as a consultant on advisory boards for Schwabe and OM Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}